Oruka Therapeutics ORKA 深 沪
已收盘 10-30 16:00:00 美东时间
96.87
+0.220
+0.23%
华盛通- 最 高97.60
- 今 开94.87
- 成交量 63.40万股
- 最 低 94.745
- 昨 收 96.65
- 总市值 64.14亿
- 52周最高 115.515
- 市盈率 静 --
- 换手率 0.96%
- 52周最低 25.23
- 委 比 53.45%
- 总股本 6620.97万
- 历史最高 5922.804
- 量 比 0.62
- 振 幅 2.95%
- 历史最低 -0.636
- 每 手 1
- 风险率 26.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅94.81%！富瑞上调ArriVent BioPharma(AVBP)目标价至30美元，维持"买入"评级
今日重点评级关注：富瑞：维持ArriVent BioPharma"买入"评级，目标价从18美元升至30美元；古根海姆：维持第一太阳能"买入"评级，目标价从282美元升至299美元
10-28 12:30
美股前瞻 | 伊朗释放和平信号！期指转涨油价回落；SK海力士盘前升逾3%，将于盘后放榜！
伊朗释放和平信号！期指转涨油价回落近1%，美债收益率下滑；SK海力士盘前升逾3%，将于盘后公布业绩；康宁、可口可乐、波音业绩齐发！汇丰控股盘前跌近7%>>
10-27 20:27
美股牛股 | Surgery Partners涨47.6%，获57亿美元私有化收购；山脉资源升17.7%，与EQT达成合并协议；Lumentum涨8.2%，获StoneX首次给予买入评级
Surgery Partners涨47.6%，获57亿美元私有化收购；山脉资源升17.7%，与EQT达成合并协议；Lumentum涨8.2%，获StoneX首次给予买入评级
10-27 16:28
Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026...
10-26 19:13
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oruka Therapeutics announced positive Week 16 results from its EVERLAST-B Phase 2b trial of ORKA-001, a novel IL-23p19 monoclonal antibody for moderate-to-severe plaque psoriasis. The high-dose group (600 mg) achieved 61% PASI 100 and 86% PASI 90, matching EVERLAST-A results. ORKA-001 showed favorable safety and tolerability, with no dose-dependent adverse events. The company plans to advance ORKA-001 into Phase 3 trials in 1H 2027, with 52-week ...
10-26 11:00
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
10-19 17:54
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Jaguar Health Stock Plunges Wednesday: What's Happening?
Jaguar Health Inc. (NASDAQ:JAGX) shares are plunging Wednesday morning as profit-taking reverses an explosive Tuesday rally sparked by regulatory fee waivers. Jaguar Health stock is taking a hit today. What’s behind JAGX decline? Low-Float Volatility and Profit-Taking The sharp downward correction f...
09-23 22:31
Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026
Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis. "These Week 28 results, with responses continuing to deepen months after the last dose, point to the incredible potential of ORKA-001," sai...
09-23 19:08
